Abstract
Therapeutic monoclonal antibody is increasingly applied in clinic with great clinical success, while its widespread application is limited by antibody manufacturing capability. Adenovirus is considered ad the one of the most proper vector for pre-clinical and clinical application, however, the application of adenoviral vector is restricted by CAR expression on the target cells. Thus adenovirus mediating anti-tumor antigen antibody expression in non-tumor cells or tumor cells is a novel strategy for cancer gene therapy. Herein we present an adenoviral delivery system that allows in vivo sufficient and sustained full-length antibody expression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
